Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 2, 2000, Pages 137-142

  Scandella, Dorothea H ^a,b  

^a HOLLAND LABORATORY   (United States)

^b AMERICAN RED CROSS   (United States)

Author keywords

Factor IX; Factor VIII; Factor X; Inhibitor antibodies; Phospholipids

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; EPITOPE;

ANTIBODY PRODUCTION; BINDING SITE; BLOOD CLOTTING; EPITOPE MAPPING; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 0033936079     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9815     Document Type: Review

References (41)

1. 1. Kane WH, Davie EW. Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988;71: 539-555
2. 2. Muntean W, Leschnik B. Factor VIII influences binding of factor IX and factor X to intact human platelets. Thromb Res 1989;55:537-548
3. 3. Gilbert GE, Drinkwater D. Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine. Biochemistry 1993;32:9577-9585
4. 4. Saenko EL, Scandella D, Yakhyaev AV, Greco NJ. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. J Biol Chem 1998;273:27918-27926
5. 5. Toole JJ, Pittman DD, Orr EC, et al. A large region (≈95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986;83:5939-5942
6. 6. Lapan K, Fay PJ. Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 1997;272:2082-2088
7. 7. Fay PJ, Haidaris PJ, Muggins CF. Role of the COOH-terminal acidic region of A1 subunit in A2 subunit retention in human factor VIIIa. J Biol Chem 1993;268:17861-17866
8. 8. Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994;269:20522-20527
9. 9. Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 1998;273:19049-19054
10. 10. Lenting PJ, van de Loo J-WHP, Donath M-JSH, van Mourik JA, Mertens K. The sequence Glu 1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996;271:1935-1940
11. 11. Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem 1991;266:21948-21955
12. 12. Saenko EL, Scandella D. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem 1995;270:13826-13833
13. 13. Nesheim M, Pittman DD, Giles AR, et al. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem 1991;266: 17815-17826
14. 14. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 1990;75:1999-2004
15. 15. Li X, Gabriel DA. The physical exchange of factor VIII (FACTOR VIII) between von Willebrand factor and activated platelets and the effect of the B-domain on platelet binding. Biochemistry 1997;36:10760-10767
16. 16. Leyte A, Verbeet MPh, Brodniewicz-Proba T, van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor; characterization of a high-affinity binding site on factor VIII. Biochem J 1989;257: 679-683
17. 17. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. A synthetic factor VIII peptide of eight amino acid residues (1677-1684) contains the binding region of an anti-factor VIII antibody which inhibits the binding of factor VIII to von Willebrand factor. Thromb Haemost 1990;63:403-406
18. 18. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994;269:11601-11605
19. 19. Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies which bind to A2. Blood 1993;82: 1767-1775
20. 20. Prescott R, Nakai H, Saenko EL, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood 1997;89:3663-3671
21. 365 of the factor VIII heavy chain. J Clin Invest 1988;82:123-128
22. 22. Foster PA, Fulcher CA, Houghten RA, de Graaf Mahoney S, Zimmerman TS. A murine monoclonal anti-factor VIII inhibitory antibody and two human factor VIII inhibitors bind to different areas within a twenty amino acid segment of the acidic region of factor VIII heavy chain. Blood Coagul Fibrinolysis 1990;1:9-15
23. 23. Lubin IM, Healey JF, Scandella D, Runge MS, Lollar P. Elimination of a major inhibitor epitope in factor VIII. J Biol Chem 1994;269:8639-8641
24. 24. Healey JF, Lubin IM, Scandella D, Lollar P. Residues 484-509 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1994;270:14505-14509
25. 25. Lubin IM, Healey JF, Barrow RT, Scandella D, Lollar P. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J Biol Chem 1997;272:30191-30195
26. 26. Lollar P, Parker ET, Curtis JE, et al. Inhibition of human factor VIIIa by human anti-A2 subunit antibodies. J Clin Invest 1994;93:2497-2504
27. 27. Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1978;83:1989-1984
28. 28. Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248-2312 which overlap a phospholipid binding site. Blood 1995;86:1811-1819
29. 29. Healey JF, Barrow RT, Tamim HM, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998;92: 3701-3709
30. 30. Eaton DL, Vehar GA. Factor VIII structure and proteolytic processing. In: Coller BS, ed. Progress in Hemostasis and Thrombosis, New York: Grune & Stratton; 1986:47-70
31. 31. Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993;69:240-246
32. 32. Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1996;2:95-99
33. 33. Fijnvandraat K, Peters M, Ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Blood 1995;91: 474-476
34. 34. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 1988;263:5230-5234
35. 35. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 1996;271:27424-27431
36. 36. Fijnvandraat K, Celie PHN, Turenhout EAM, et al. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood 1998;91:2347-2352
37. 37. Zhong D, Saenko EL, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998;92:136-142
38. 38. McMillan CW, Shapiro SS, Whitehurst D, et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988;71:344-348
39. 593 to Cys mutation. Blood 1997;90: 1902-1910
40. 40. Fijnvandraat K, Turenhout EAM, van den Brink EN, et al. The missense mutation Arg593 → Cys is related to antibody formation in a patient with mild hemophilia A. Blood 1997;89: 4371-4377
41. 41. Sawamoto Y, Prescott R, Zhong D, et al. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost 1998;79:62-68